Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
01. Dezember 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
23. November 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
17. November 2022 07:00 ET
|
Krystal Biotech, Inc.
Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration of high dose KB301Mean change in Subject Satisfaction Scores from baseline...
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
07. November 2022 07:00 ET
|
Krystal Biotech, Inc.
• Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023 • Notified of no...
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
29. September 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsichtlich des pädiatrischen Prüfkonzepts für B-VEC bei der Behandlung von dystropher Epidermolysis bullosa
22. September 2022 18:32 ET
|
Krystal Biotech, Inc.
• Das Unternehmen befindet sich im Zeitplan, um im vierten Quartal 2022 einen Zulassungsantrag für Europa zu stellen • Es sind keine weiteren Studien erforderlich PITTSBURGH, Sept. 23, 2022...
Krystal Biotech reçoit un avis positif de la part du Comité pédiatrique de l'EMA pour son plan d'investigation pédiatrique sur B-VEC pour le traitement de l'épidermolyse bulleuse dystrophique
22. September 2022 18:32 ET
|
Krystal Biotech, Inc.
• La Société est sur la bonne voie pour soumettre sa demande de mise sur le marché européen au 4e trimestre 2022 • Aucune étude supplémentaire n'est requise PITTSBURGH, 23 sept. 2022 (GLOBE...
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
21. September 2022 16:30 ET
|
Krystal Biotech, Inc.
• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”)...
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
08. September 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
18. August 2022 17:00 ET
|
Krystal Biotech, Inc.
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 ...